Claims for Patent: 9,073,987

Summary for Patent: 9,073,987

Title:	Methods of administering anti-TNFα antibodies
Abstract:	Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Inventor(s):	Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
Assignee:	AbbVie Biotechnology Ltd
Application Number:	US14/292,759

Details for Patent 9,073,987

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009		2034-05-30
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009		2034-05-30

International Patent Family for US Patent 9,073,987

Country	Patent Number	Estimated Expiration
South Africa	200308861
World Intellectual Property Organization (WIPO)	02100330
United States of America	9546212